CME Corner

Program Detail

Faculty

Chair
Tuhina Neogi, MD, PhD
Associate Professor of Medicine and Epidemiology
Boston University School of Medicine
Boston, MA

Naomi Amudala, MSN, RN, FNP-BC
Clinical Instructor and Nurse Practitioner
Vasculitis Center/Rheumatology
Boston University School of Medicine
Boston, MA

Nancy Figueiredo, RN
Rheumatology Nurse
Boston Medical Center
Boston, MA

Patient Advocate
Saralynn Allaire, ScD

Credit Hours

Physicians: 1.0 AMA PRA Category 1 Credit^TM
Nurses: 1.0 ANCC contact hour and 0.3 advanced practice nurse pharmacology contact hour

Medium

Video Roundtable

Program Description

The goal of this expert roundtable discussion is to expand the ability of rheumatology clinicians to implement best practices in the management of RA based on the latest clinical evidence. RA currently affects approximately 1.3 million people in the United States. Without early treatment that emphasizes tight control of disease activity, RA progresses to cause joint destruction, decreased physical functioning, and reduced quality of life. Early treatment initiation, ongoing monitoring of therapeutic response, and appropriate treatment adjustments are critical to improving patient outcomes. With the availability of new treatment guidelines and evolving research data, it is imperative that rheumatologists and other clinicians specializing in rheumatology learn about new developments, data, and recommendations for the treatment of RA.

Program Developer/Facilitator

This activity is co-provided by The University of Chicago Pritzker School of Medicine, Postgraduate Institute for Medicine, and MCM Education.

Target Audience

This activity is intended for rheumatology clinicians including physicians, PAs, NPs, and RNs.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

1. Utilize current guideline-based treatment options for patients with early RA.
2. Define appropriate RA treatment targets based on individual characteristics and disease presentation.
3. Incorporate the appropriate use of validated composite measures of disease activity for patients with RA.
4. Discuss the characteristics of DMARDs that may be appropriate for patients with established RA, including their efficacy, safety, and use in combination regimens.
5. Outline the disease and patient factors that would influence DMARD selection.
6. Implement approaches for increasing patient collaboration and shared decision making when developing individualized treatment plans.
7. Discuss emerging investigational therapies for RA in late stages of clinical development.
8. Provide appropriate care and counsel for patients and their families.

Disclosures

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational activities. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and the credit providers have a process in place to resolve any conflict of interest.

Tuhina Neogi, MD, PhD, has nothing to disclose.
Naomi Amudala, MSN, RN, FNP-BC, has nothing to disclose.
Nancy Figueiredo, RN, discloses that she has served on the speakers' bureau for AbbVie, Inc.
Saralynn Allaire, ScD, has nothing to disclose.

The University of Chicago Pritzker School of Medicine staff involved in the development and review of this activity have nothing to disclose.

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Anne Jacobson, MCM Medical Writer, has nothing to disclose.
Kathleen Hines, MCM Education Editorial Director, has nothing to disclose.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Credit Statements

Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and MCM Education. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s).^TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

Designated for 0.3 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed online activity evaluation.

For questions regarding the CNE/nursing credit, contact Postgraduate Institute for Medicine at (800) 423-3576 or information@pimed.com.

Credit is awarded to participants who score 80% or better on the post-test.

The online activity will take approximately 60 minutes to complete.

Commercial Support Statements

Supported by an independent educational grant from AbbVie, Inc and Lilly.

Instructions

1. There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
2. Review the intended audience, learning objectives, and author disclosures.
3. Study the educational content online.
4. Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
5. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee

$0.00

Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, The University of Chicago Pritzker School of Medicine, Postgraduate Institute for Medicine, AbbVie, or Lilly. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.